Leukemia Research
Volume 29, Issue 8 , Pages 967-969 , August 2005

Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide

Received 13 December 2004

References 

  1. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia. 2004;18:1476–1481
  2. Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Duechler M, Gisslinger H. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest. 2004;113:676–685
  3. Aziz KA, Till KJ, Chen H, Slupsky JR, Campbell F, Cawley JC, et al. The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL). Blood. 2003;102:1051–1056[Epub., April 10, 2003]
  4. Gruber G, Schwarzmeier JD, Shehata M, Hilgarth M, Berger R. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. Blood. 1999;94:1077–1085
  5. Aziz KA, Till KJ, Zuzel M, Cawley JC. Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia. Blood. 2000;96:3161–3167
  6. Korkolopoulou P, Gribabis DA, Kavantzas N, Angelopoulou MK, Siakantaris MP, Patsouris E, et al. A morphometric study of bone marrow angiogenesis in hairy cell leukaemia with clinicopathological correlations. Br J Haematol. 2003;122:900–910
  7. Pruneri G, Bertolini F, Baldini L, Valentini S, Goldaniga M, Soligo D, et al. Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. Br J Haematol. 2003;120:695–698
  8. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004;79:883–889
  9. Piccaluga PP, Visani G, Pileri SA, Ascani S, Grafone T, Isidori A, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia. 2002;16:1609–1614
  10. Damaj G, Lefrere F, Delarue R, Varet B, Furman R, Hermine O. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia. 2003;17:1914–1915
  11. Kaufmann H, Raderer M, Woehrer S, Puespoek A, Bankier A, Zielinski C, et al. Anti-tumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood. 2004;May 27:[Epub. ahead of print]
  12. Pro B, Younes A, Albitar M, Dang NH, Samaniego F, Romaguera J, et al. Thalidomide for patients with recurrent lymphoma. Cancer. 2004;100:1186–1189
  13. Sugimori C, Kaito K, Nakao S. Persistent remission after immunosuppressive therapy of hairy cell leukemia mimicking aplastic anemia: two case reports. Int J Hematol. 2003;77:391–394
  14. Dedic K, Zak P. Effect of 2-chlorodeoxyadenosine therapy on bone marrow fibrosis in hairy cell leukemia. Neoplasma. 2004;51:56–58
  15. Crivellato E, Nico B, Vacca A, Ribatti D. B-cell non-Hodgkin's lymphomas express heterogeneous patterns of neovascularization. Haematologica. 2003;88:671–678
  16. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–4085
  17. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Am Rheum Dis. 1999;58:107–113
  18. Marriot JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clin Exp Immunol. 2002;130:75–84
  19. Singhal S, Metha J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571
  20. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002;16:1–6
  21. Strupp C, Aivado M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymph. 2002;43:133–137

PII: S0145-2126(05)00051-2

doi: 10.1016/j.leukres.2005.01.007

Leukemia Research
Volume 29, Issue 8 , Pages 967-969 , August 2005

Article Tools